NEW YORK, June 30, 2026
Inductive Bio, Inc. has announced its integration into Anthropic’s Connector Ecosystem for Life Sciences, introducing a new Model Context Protocol (MCP) connector that enables scientists to access state-of-the-art ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) prediction models directly through Claude. The collaboration marks a significant advancement in AI-driven drug discovery, allowing medicinal chemists and drug development teams to evaluate critical molecular properties using natural language within their existing research workflows. By embedding advanced machine learning-based ADMET prediction into Claude and Claude Science, researchers can rapidly analyze chemical structures, assess pharmacokinetic and toxicity profiles, and optimize compound design without switching between multiple software platforms. The innovation is expected to streamline decision-making during early-stage drug discovery while enabling pharmaceutical researchers to identify promising therapeutic candidates more efficiently. The announcement further reinforces the growing adoption of artificial intelligence, predictive modeling, and virtual chemistry platforms as essential technologies for accelerating the development of safer and more effective medicines.
AI Integration Simplifies Drug Discovery Workflows
The newly launched Inductive Bio MCP connector provides scientists with seamless access to globally validated ADMET prediction models directly within Claude, enabling researchers to evaluate the pharmacological behavior of small molecules through simple conversational interactions. Traditionally, assessing absorption, distribution, metabolism, excretion, and toxicity requires multiple computational tools and extensive laboratory validation, creating one of the most time-consuming stages of pharmaceutical research. Through the new integration, researchers can upload chemical structures, receive immediate predictions for critical ADMET properties, and interpret those findings alongside broader medicinal chemistry discussions without leaving the AI workspace.
This unified environment supports faster hypothesis generation, compound optimization, and lead candidate selection while improving collaboration across multidisciplinary drug discovery teams. By reducing workflow complexity, the connector enables scientists to spend more time refining therapeutic strategies and less time navigating fragmented computational platforms.
Award-Winning ADMET Models Advance Precision Drug Design
Advertisement
Inductive Bio’s predictive models have earned industry recognition for their exceptional accuracy, ranking first among more than 370 submissions from leading pharmaceutical companies and AI organizations during the OpenADMET-ExpansionRx blind challenge. These machine learning models address one of the most persistent challenges in small-molecule drug discovery by helping researchers balance therapeutic potency with critical pharmacokinetic and safety characteristics that determine whether a candidate can become a successful medicine.
Beyond standard ADMET prediction, the company also offers advanced pharmacokinetic (PK) modeling, AI-powered medicinal chemistry support, and virtual laboratory technologies that enable researchers to evaluate numerous drug candidates before initiating laboratory experiments. Importantly, Inductive Bio emphasized that chemical structures submitted through Claude are not retained or used to train its machine learning models, ensuring that proprietary scientific data remains protected while organizations continue developing confidential therapeutic programs.
Virtual Chemistry Labs Accelerate Biopharmaceutical Innovation
The collaboration with Anthropic further strengthens Inductive Bio’s vision of building virtual chemistry laboratories capable of integrating artificial intelligence, computational chemistry, predictive biology, and digital organ technologies into a unified drug discovery platform. These technologies enable pharmaceutical and biotechnology companies to evaluate more molecular hypotheses in silico, identify potential development risks earlier, and prioritize the highest-quality candidates before laboratory testing. By combining AI chemistry assistants, advanced ADMET prediction, pharmacokinetic modeling, and human-relevant digital biology, researchers can shorten discovery timelines while improving decision quality throughout the development process. The integration into Anthropic’s Life Sciences Connector Ecosystem represents another important milestone in the evolution of AI-enabled pharmaceutical research, demonstrating how intelligent computational platforms are transforming medicinal chemistry, reducing drug discovery costs, and accelerating the development of innovative therapies for patients worldwide.
Source: Inductive Bio press release
